CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用 BiTE 抗击淋巴瘤：B 细胞非霍奇金淋巴瘤中的双特异性抗体
英文原题：Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
查看英文原题
Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
B 细胞非霍奇金淋巴瘤（NHL）是一组异质性疾病，治疗策略多样，患者结局差异较大。过去十年，NHL 已有多种新型免疫疗法获批，包括双特异性抗体（BsAb）和CAR-T 细胞疗法（CAR-T）。随着新疗法不断涌现，下一步的重要任务是确定这些疗法在当前治疗方案中的使用顺序。本综述旨在提供框架，说明如何将 BsAb 纳入 NHL 现行管理模式，尤其关注弥漫性大 B 细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）。
展开英文摘要原文
B-cell non-Hodgkin's lymphoma (NHL) refers to a heterogenous group of diseases, all of which have a wide range of treatment strategies and patient outcomes. There have been multiple novel, immune-based therapies approved in NHL in the last decade, including bispecific antibodies (BsAbs) and chimeric antigen receptor therapy (CAR-T).
With a host of new therapies, an important next step will be determining how these therapies should be sequenced in contemporary management strategies. This review seeks to offer a framework for the ways in which BsABs can be incorporated into the current management paradigm for NHL, with special attention paid to diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
论文信息
- 作者
- Weiss JM、Phillips TJ
- 第一作者单位
- Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.United States
- 通讯作者单位
- City of Hope Comprehensive Cancer Center, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, Duarte, CA 91010, USA.United States
- 文献类型
- 综述
- 期刊
- Cancers2024 Apr 28
- 原文标识
- PubMed 38730677 · DOI 10.3390/cancers16091724
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →